Skip to main content
. 2021 May 17;3(2):zcab018. doi: 10.1093/narcan/zcab018

Figure 6.

Figure 6.

Combination of ATRi and PRAPi was effective in IDH1-mutant mouse xenograft model. (A) Athymic nude mice received subcutaneous injection of HCT116 IDH1 R132H/+ or HT1080 IDH1 R132C/+ cells. Twelve days after injection, the hind flank tumors were measured and equally distributed to four-arm treatment groups (B) Left panel: Mice carrying flank tumors of HCT116 R132H/+ cells were treated with no treatment (n = 8), Olaparib alone (50 mg/kg) (n = 8), AZD6738 (50 mg/kg) (n = 8), or Olaparib (50 mg/kg) and AZD6738 (50 mg/kg) (n = 8). Mice were treated daily for 28 days. Mean tumor volume per group with SEM is plotted on y-axis. Right panel: mean body weight with SEM of mice during HCT116 IDH1 R132H/+ flank tumor experiment. (C) Left panel: mice carrying flank tumors of HT1080 'cells were treated with no treatment (n = 7), Olaparib alone (50 mg/kg) (n = 7), AZD6738 (50 mg/kg) (n = 7), or Olaparib (50 mg/kg) and AZD6738 (50 mg/kg) (n = 8). Mice were treated daily for 28 days. Right panel: mean body weight with SEM of mice during HT1080 flank tumor experiment. (D) Left panel: mice carrying flank tumors of HCT116 R132H/+ cells were treated with no treatment (n = 5), Olaparib alone (25 mg/kg) (n = 5), AZD6738 (25 mg/kg) (n = 5), or Olaparib (25 mg/kg) and AZD6738 (25 mg/kg) (n = 5). Mice were treated daily for 21 days. Mean tumor volume per group with SEM is plotted on y-axis. Right panel: mean body weight with SEM of mice during HCT116 R12H/+ flank tumor experiment. Error bars represent means ± SEM. P values were calculated using two-way ANOVA.